^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Non Small Cell Lung Cancer
    Drug:luminespib (AUY922) (HSP90 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    AUY922 in Patient With Stage IV NSCLC

    Excerpt:
    ...Positive ALK results from other methods such as immunohistochemistry (IHC) or reverse transcriptase polymerase chain reaction testing may also be acceptable....
    Trial ID:
    NCT01922583
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK+) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

    Excerpt:
    Pts with advanced NSCLC who progressed following ≥1 prior line of chemotherapy, received AUY922 (70 mg/m2 ) as a once-weekly, 1-hr infusion….Clinical activity of AUY922 was seen in pts with ALK+ and EGFR-mut NSCLC, with partial responses in 6/21 (29%) pts and 7/35 (20%) pts, respectively...
    DOI:
    10.1093/annonc/mds395